This secondary analysis of a prospective longitudinal study investigates whether anthracycline chemotherapy confers greater risk of cognitive decline for breast cancer survivors compared with nonanthracycline-based chemotherapy.
No takes yet. Share an insight, caveat, or question.
Dyk et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: